180340-70-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-amino-5-bromonicotinate is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to be easily modified and incorporated into complex molecular structures. Its presence of a bromine atom and an amino group on the nicotinic acid ring allows for versatile chemical reactions, making it a valuable building block in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 6-amino-5-bromonicotinate is utilized as a reagent or precursor for the creation of a wide range of organic compounds. Its unique functional groups enable it to participate in various chemical reactions, contributing to the synthesis of target molecules with specific properties and applications.
Used in Drug Discovery and Development:
Methyl 6-amino-5-bromonicotinate is employed as a potential lead compound in drug discovery due to its structural similarity to other bioactive molecules. Researchers can use Methyl 6-amino-5-bromonicotinate as a starting point to explore its pharmacological properties and optimize its structure for specific therapeutic applications, potentially leading to the development of new medications.

Upstream product

• 3167-49-5 6-aminonicotinic acid 
• 36052-24-1 methyl 6-aminonicotinoate 
• 180340-69-6 6-Amino-5-bromopyridine-3-carboxylic acid 

Downstream Products

• 1622880-27-6 C₂₃H₂₇N₅O₃ 
• 1622905-84-3 C₂₄H₂₉N₅O₄ 
• 1622905-85-4 C₂₅H₂₉N₅O₄ 
• 1622905-86-5 C₂₄H₂₇N₅O₅ 
• 1622880-28-7 C₂₅H₃₂N₆O₃ 
• 1622905-88-7 C₂₇H₃₅N₇O₃ 
• 1622905-89-8 C₂₄H₂₈N₄O₅ 
• 1622905-90-1 C₂₅H₃₀N₄O₅ 
• 1622905-91-2 C₂₅H₃₀N₄O₅ 
• 1622905-92-3 C₂₄H₂₇FN₄O₅ 
• 1622905-93-4 C₂₅H₂₇N₅O₅ 
• 1622905-94-5 C₂₅H₃₀N₄O₆ 
• 1622905-95-6 C₂₅H₃₀N₄O₆ 
• 1622905-96-7 C₂₅H₂₉FN₄O₅ 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

TRICYCLIC THIENO-AZEPINE VASOPRESSIN ANTAGONISTS

This invention relates to new bicyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.